The group abandons plans in lung cancer with Met exon 14 skipping, to focus on Met amplifications.

One of the German group’s biggest cancer hopes has fallen flat, raising more questions about targeting an apoptosis pathway.

This weekend’s oncology conference will feature at least 30 different ADC projects.

ASCO is fast approaching, but in the meantime Olema will have an important readout.

One of the first human datasets concerning an ATM inhibitor shows glioblastoma’s intractability.

Selectively hitting PARP1 is meant to reduce toxicity, and arguably the Petra trial shows this.

BeiGene has a strong presence at this year’s AACR, which features several notable duels.

Three years after licensing in the IAP inhibitor xevinapant Merck KGaA will find out if the deal was worth it.